alpha-L-iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype.

Article Details

Citation

Scott HS, Litjens T, Nelson PV, Brooks DA, Hopwood JJ, Morris CP

alpha-L-iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype.

Hum Mutat. 1992;1(4):333-9. doi: 10.1002/humu.1380010412.

PubMed ID
1301941 [ View in PubMed
]
Abstract

Mucopolysaccharidosis type I (MPS-I) is an autosomal recessive genetic disease caused by a deficiency of the glycosidase alpha-L-iduronidase which is required for the lysosomal degradation of the glycosaminoglycans heparan sulfate and dermatan sulfate. Patients with MPS-I store forms of these partially degraded glycosaminoglycans in their lysosomes. MPS-I patients present with a wide range of clinical phenotypes, which makes prognostic predictions and genetic counselling difficult, therefore impeding the selection and evaluation of patients undergoing experimental therapy, such as bone marrow transplantation. We report the presence of two mutations, one that introduces a stop codon at position 70 (Q70X), and the other that alters the proline at position 533 to an arginine (P533R) in the 653 amino acid alpha-L-iduronidase protein. These mutations were originally detected by chemical cleavage and then by direct PCR sequencing. Allele specific oligonucleotides were used to detect the mutations in a group of 73 MPS-I patients and Q70X was found to account for 15% of all MPS-I alleles and P533R for 3% of MPS-I alleles. Both mutations are associated with an extremely severe clinical phenotype in homozygotes. MPS-I patients heterozygous for either mutation may have a wide range of clinical phenotypes. We have now described three mutations, W402X (Scott et al., 1992c), Q70X, and P533R totalling 53% of MPS-I alleles which together define 28% of MPS-I genotypes.

DrugBank Data that Cites this Article

Polypeptides
NameUniProt ID
Alpha-L-iduronidaseP35475Details